History

Epitalon comes from the work of Russian gerontologist Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, beginning in the 1980s-1990s. It is a synthetic analogue of epithalamin, a peptide extract from the pineal gland that Soviet and Russian researchers had studied for effects on aging and neuroendocrine regulation. Khavinson distilled the activity to the tetrapeptide Ala-Glu-Asp-Gly. Most published research — on telomeres, melatonin, immune function, and lifespan in animals — comes from Khavinson's group, with limited independent replication outside Russia.

Epitalon (also spelled Epithalon) is a synthetic four-amino-acid peptide that has become a fixture of the “longevity” and anti-aging marketplace. It is sold with some of the boldest claims in the peptide world, and some of the thinnest independent evidence to back them up.

What it is

Epitalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, and is the synthetic counterpart of the proposed active fragment of epithalamin (epithalamin being an extract of the pineal gland). Almost all of the foundational research comes from this single Russian research group.

The claims

Vendors and clinics promote Epitalon as a telomere-lengthening, telomerase-activating “anti-aging” compound that resets circadian rhythm, restores melatonin, slows biological aging, and reduces mortality. The strongest marketing claims describe it as extending human lifespan.

What the evidence actually shows

Most of the data is preclinical. In cells and in animals (flies, mice, rats), Epitalon has been reported to raise telomerase activity, lengthen telomeres, increase melatonin synthesis, and modestly extend lifespan in some strains. A 2025 review notes these effects but cautions that its mechanism of action remains unclear and that it is not known whether these are even the compound’s actual routes of action.

Human evidence on the synthetic peptide itself is limited and weak by modern standards. The 2025 review identified only two clinical trials of Epitalon: a non-randomized study in 162 retinitis pigmentosa patients reporting improved visual measures, and a small placebo-controlled trial in 75 women reporting increased melatonin (about 1.6-fold versus placebo) and altered clock-gene expression over 20 days.

A frequently cited mortality benefit comes from a different substance. A prospective cohort of 266 people over 60 reported a 1.6–1.8-fold lower mortality over six years, and a related cohort combining thymus and pineal peptides reported a larger reduction over longer follow-up. Those studies used epithalamin, the pineal-gland extract, and a thymic peptide preparation — not synthetic Epitalon — and the 2025 review did not count them among the peptide’s own clinical trials. They should not be read as direct evidence for Epitalon.

Taken together, these are small, mostly short, mostly observational, single-center studies from one research lineage, with no independent Western replication in living humans and no large randomized trials. They cannot establish that Epitalon slows aging or extends human lifespan. (A 2025 cell-culture study has independently reproduced telomere lengthening in human cell lines, but that is a laboratory finding, not a human clinical outcome.)

Legal and regulatory status

As of June 2026, Epitalon is not approved by the FDA for any use and is not a lawful dietary supplement ingredient. In April 2026 the FDA removed Epitalon, along with eleven other peptides, from Category 2 of its compounding review (the “significant safety concerns” bucket), and its Pharmacy Compounding Advisory Committee is scheduled to consider these substances for the 503A bulks list on July 23–24, 2026 (Epitalon is on the July 24 agenda). Removal from Category 2 is not approval and does not by itself authorize compounding; it signals reconsideration, not endorsement. Epitalon is not explicitly named on the WADA Prohibited List, but as a non-approved substance it falls under category S0 (substances prohibited at all times). Athletes should treat it as prohibited and verify status directly.

Safety

Human safety is essentially uncharacterized. The 2025 review states plainly that information on this peptide’s safety is missing and that short- and long-term toxicity studies — including genotoxicity and carcinogenicity — are needed before it could be considered a pharmaceutical ingredient. Reported trials note no obvious side effects, but they were too small and too short to detect uncommon or delayed harms, and a compound that upregulates telomerase carries theoretical proliferation concerns that have not been resolved in humans. Most material sold online is unregulated and not made to pharmaceutical standards, adding contamination and dosing risks. None of this is medical advice.

Bottom line

Epitalon has intriguing preclinical findings and a handful of small, early human studies from a single research lineage — two of them in the synthetic peptide, with the headline mortality data coming from the related pineal extract rather than Epitalon itself. The lifespan and anti-aging claims are not supported by the kind of large, independent, randomized human trials that would justify them, and its safety profile in humans is largely unknown.

Evidence grade: Preliminary human.

Epitalon (Epithalon): What the Evidence Actually Shows